Dilip Shanghvi is the founder and managing director of Sun Pharmaceutical Industries, India’s largest drugmaker. Despite lacking a science background, Shanghvi’s business acumen has transformed Sun Pharma into a global leader in specialty generics. 

Starting small in 1982, he grew the company through strategic acquisitions, most notably the controversial purchase of Ranbaxy in 2014. While some criticize his aggressive tactics, Shanghvi’s focus on research and development has ensured Sun Pharma’s continued growth. 

Looking ahead, he seemingly prioritizes maintaining Sun Pharma’s lead in the generics market while potentially venturing into areas like biosimilars, capitalizing on his strong foundation in pharmaceuticals. Indiaspora is proud to have Dillip Shanghvi in our Biz Leaders List for 2024.